Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA acting CIO to depart

Executive Summary

FDA Acting Chief Information Officer Fred Farmer is leaving to return to a career in the private sector, effective July 22. Farmer assumed the role of acting CIO following the departure of CIO Jim Rinaldi last year (1"The Pink Sheet" Aug. 1, 2005, In Brief). FDA Associate Commissioner for Management and CFO Kathleen Heuer will assume the role of acting CIO as the agency completes its search for a permanent replacement...

You may also be interested in...

FDA information technology

FDA Information Technology Program Director Fred Farmer will become acting chief information officer Aug. 1 until a permanent replacement is found for departing CIO Jim Rinaldi. Rinaldi has accepted the CIO position with NASA's Jet Propulsion Laboratory; he became FDA's CIO in December 2002 ( 1"The Pink Sheet" Jan. 13, 2003, In Brief)...

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.

What’s Next? Five Things To Look Out For In March

In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts